GlassScriptPhysician profile
Michael W Chapman
NPI 1013952050
$247.33
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.37 · 2021: $134 · 2022: $53.68 · 2023: $16.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $57.03 | 2021 | |
| Abbvie INC. | $39.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $35.02 | 2021 | |
| Lilly USA, LLC | $28.93 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $16.83 | 2023 | |
| Genentech USA, INC. | $15.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.04 | 2022 | |
| Novo Nordisk INC | $13.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.